Biography

Download Curriculum Vitae

Marc Diamond, M.D., is the founding Director of the Center for Alzheimer’s and Neurodegenerative Diseases, and is a Professor of Neurology and Neurotherapeutics. Dr. Diamond completed an internship, residency, and chief residency in neurology at the University of California, San Francisco (UCSF) in 1997. After a postdoctoral fellowship, he was a faculty member in the Neurology Department at UCSF from 2002-2009. From 2009-2014 he was the David Clayson Professor of Neurology at Washington University in St. Louis, before he was recruited to UT Southwestern. His research focuses on molecular mechanisms of neurodegeneration in Alzheimer’s disease and related disorders, with the goal of developing novel therapies and diagnostic tools. A therapeutic antibody he co-developed at Washington University in St. Louis is now entering clinical trials for treatment of dementia. The Center for Alzheimer’s and Neurodegenerative Diseases is comprised of a multidisciplinary group of investigators who are focused on understanding the basis of progressive protein aggregation in human disease. They are using this knowledge to hasten the day when neurodegeneration can be detected presymptomatically and stopped before it causes disability.

Education

Graduate School
Princeton University (1987), History
Medical School
University of California-San F (1993), Medicine

Research Interest

  • Cell and Molecular Biology
  • Neurodegenerative Diseases
  • Neuroscience
  • Prion Biology

Publications

Featured Publications LegendFeatured Publications

Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance vs. blocking neuronal uptake.
Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI J. Biol. Chem. 2015 Jun
Subcellular Localization and Ser-137 Phosphorylation Regulate Tumor-Suppressive Activity of Profilin-1.
Diamond MI, Cai S, Boudreau A, Carey CJ, Lyle N, Pappu RV, Swamidass SJ, Bissell M, Piwnica-Worms H, Shao J J. Biol. Chem. 2015 Feb
The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios.
Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J FEBS Lett. 2015 Jan 589 1 77-83
Proteopathic tau seeding predicts tauopathy in vivo.
Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI Proc. Natl. Acad. Sci. U.S.A. 2014 Sep
Distinct tau prion strains propagate in cells and mice and define different tauopathies.
Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI Neuron 2014 Jun 82 6 1271-88
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM Neuron 2013 Oct 80 2 402-14
Advances in diagnostic testing for Alzheimer disease.
Schindler SE, McConathy J, Ances BM, Diamond MI Mo Med 2013 Sep-Oct 110 5 401-5
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.
Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI Proc. Natl. Acad. Sci. U.S.A. 2013 Aug 110 33 E3138-47

Honors & Awards

  • Distinguished Chair
    Brain Injury and Repair (2014)
  • Scholar-Innovator Award
    Harrington (2012)
  • Foundation Award
    Ruth K. Broad (2010)
  • Endowed Chari
    David Clayson Professor of Neurology (2009)
  • Leadership Award
    Huntington's Disease Society of America (2007)
  • Sandler Opportunity Award
    (2007)